4-Year Follow-Up of Pembrolizumab in Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
KEYNOTE-013 4-Year Follow-Up of Pembrolizumab in Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
Blood Adv 2020 Jun 23;4(12)2617-2622, P Armand, J Kuruvilla, JM Michot, V Ribrag, PL Zinzani, Y Zhu, P Marinello, A Nahar, CH MoskowitzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.